Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
Date:7/22/2009

THE WOODLANDS, Texas, July 22 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2009 financial results on Tuesday, July 28, 2009 before the financial markets open. Lexicon management will hold a conference call to discuss its clinical development progress and financial results for second quarter 2009 at 11:00 a.m. Eastern Time on July 28, 2009.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 17788499. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through August 4, 2009.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
2. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
3. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
4. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
5. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
6. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
7. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
11. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments (SSI) ... 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test ... Expo attendees can stop by booth 1021 to learn how Shimadzu’s instruments can ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... 27, 2016 , ... A compact PET scanner called NuPET™ ... (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary ... subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers ...
(Date:4/27/2016)... 2016 ReportsnReports.com adds 2016 ... focus on US, EU, China ... the healthcare business intelligence collection of its growing ... report on the Flow Cytometry market spread across ... 282 tables and figures is now available at ...
Breaking Biology Technology:
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
(Date:3/10/2016)... Pa. , March 10, 2016   Unisys Corporation ... Customs and Border Protection (CBP) is testing its biometric ... San Diego to help identify certain non-U.S. ... . The test, designed to help determine the efficiency ... environment, began in February and will run until May 2016. ...
Breaking Biology News(10 mins):